Identity
HGNC
LOCATION
6q21
LOCUSID
ALIAS
CT2,FLIPT2,HEL-S-18,OAT6,OCT6,OKB1,dJ261K5.1
FUSION GENES
Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 85413
MIM: 608276
HGNC: 20302
Ensembl: ENSG00000004809
Variants:
dbSNP: 85413
ClinVar: 85413
TCGA: ENSG00000004809
COSMIC: SLC22A16
RNA/Proteins
Expression (GTEx)
Pathways
Protein levels (Protein atlas)
PharmGKB
| Entity ID | Name | Type | Evidence | Association | PK | PD | PMIDs |
|---|---|---|---|---|---|---|---|
| PA128406956 | fluorouracil | Chemical | ClinicalAnnotation | associated | PD | ||
| PA165291922 | doxorubicinol | Chemical | ClinicalAnnotation | associated | PK | PD | 17559346 |
| PA443560 | Breast Neoplasms | Disease | ClinicalAnnotation | associated | PK | PD | 17559346, 20179710, 28036387 |
| PA449165 | cyclophosphamide | Chemical | ClinicalAnnotation | associated | PD | 20179710, 28036387 | |
| PA449412 | doxorubicin | Chemical | ClinicalAnnotation | associated | PK | PD | 17559346, 20179710, 28036387 |
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 32727751 | 2020 | Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer. | 4 |
| 32727751 | 2020 | Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer. | 4 |
| 29698084 | 2018 | SLC22A16 upregulation is an independent unfavorable prognostic indicator in gastric cancer. | 9 |
| 29698084 | 2018 | SLC22A16 upregulation is an independent unfavorable prognostic indicator in gastric cancer. | 9 |
| 28036387 | 2016 | Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. | 11 |
| 28036387 | 2016 | Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. | 11 |
| 25772757 | 2015 | Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. | 12 |
| 25998464 | 2015 | Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. | 29 |
| 26314988 | 2015 | Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. | 32 |
| 26499074 | 2015 | Transduction of Oct6 or Oct9 gene concomitant with Myc family gene induced osteoblast-like phenotypic conversion in normal human fibroblasts. | 14 |
| 25772757 | 2015 | Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. | 12 |
| 25998464 | 2015 | Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. | 29 |
| 26314988 | 2015 | Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. | 32 |
| 26499074 | 2015 | Transduction of Oct6 or Oct9 gene concomitant with Myc family gene induced osteoblast-like phenotypic conversion in normal human fibroblasts. | 14 |
| 20037140 | 2010 | The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. | 46 |
Citation
Dessen P
SLC22A16 (solute carrier family 22 member 16)
Atlas Genet Cytogenet Oncol Haematol. 2007-02-01
Online version: http://atlasgeneticsoncology.org/gene/46047/slc22a16
